Vancomycin in Primary Sclerosing Cholangitis in Italy
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There
is still no medical therapy proven to halt the progression of PSC or prevent its serious
complications.
This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating
the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in
subject between 15 - 70 years old with PSC.